1. Academic Validation
  2. HBx-induced HSPA8 stimulates HBV replication and suppresses ferroptosis to support liver cancer progression

HBx-induced HSPA8 stimulates HBV replication and suppresses ferroptosis to support liver cancer progression

  • Cancer Res. 2023 Feb 6;CAN-22-3169. doi: 10.1158/0008-5472.CAN-22-3169.
Yufei Wang 1 Man Zhao 2 Lina Zhao 1 Yu Geng 3 Guanghao Li 4 Lin Chen 5 Jingxuan Yu 3 Hongfeng Yuan 2 Huihui Zhang 1 Haolin Yun 2 Ying Yuan 2 Guowen Wang 4 Jinyan Feng 6 Liang Xu 7 Shuai Wang 4 Chunyu Hou 8 Guang Yang 1 Ning-Ning Zhang 1 Wei Lu 1 Xiaodong Zhang 1
Affiliations

Affiliations

  • 1 Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
  • 2 Nankai University, Tianjin, China.
  • 3 Nankai University, China.
  • 4 Tianjin Medical University Cancer Institute and Hospital, China.
  • 5 Tianjin Second People's Hospital, China.
  • 6 Tianjin Medical University Cancer Institute and Hospital, tianjin, China.
  • 7 Tianjin Second People's Hospital, Tianjin, China.
  • 8 Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China.
Abstract

Hepatitis B virus (HBV) Infection is a major driver of hepatocarcinogenesis. Ferroptosis is a type of iron-mediated cell death that can suppress liver transformation. Previous studies have linked HBV to Ferroptosis in liver fibrosis and acute liver failure. However, whether Ferroptosis is involved in HBV-mediated liver Cancer is poorly understood. Here, we identified heat shock protein family A member 8 (HSPA8) as a crucial host factor that modulates HBV replication and Ferroptosis in liver Cancer. Hepatitis B X protein (HBx) upregulated HSPA8 by coactivating the transcription factor heat shock factor 1 (HSF1) in cells. HSPA8 enhanced HBV replication by recruiting hepatitis B core protein (HBc) to the HBV covalently closed circular DNA (cccDNA) minichromosome, forming a positive feedback loop. Moreover, HSPA8 suppressed Ferroptosis in liver Cancer cells by upregulating expression of SLC7A11/GPX4 and decreasing erastin-mediated ROS and Fe2+ accumulation in cells in vitro and in vivo. Inhibition of HSPA8 reduced the growth of HBV-positive liver tumors and increased sensitivity to erastin. In conclusion, HBx-elevated HSPA8 regulates both HBV replication and Ferroptosis in liver Cancer. Targeting HSPA8 could be a promising strategy for controlling HBV and hepatocarcinogenesis.

Figures
Products